Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Vedolizumab
- Indications Psoriasis
- Focus Pharmacodynamics; Pharmacogenomic; Proof of concept
- Acronyms STRAUSS
Most Recent Events
- 27 Jun 2024 Status changed from not yet recruiting to completed.
- 21 Aug 2018 New trial record